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ARTICLE
Dimethyl fumarate is an allosteric covalent inhibitor
of the p90 ribosomal S6 kinases
Jacob Lauwring Andersen1, Borbala Gesser2, Erik Daa Funder3, Christine Juul Fælled Nielsen1,
Helle Gotfred-Rasmussen1, Mads Kirchheiner Rasmussen2,4, Rachel Toth5,6, Kurt Vesterager Gothelf 3,
J. Simon C. Arthur5,6, Lars Iversen2,4 & Poul Nissen 1
Dimethyl fumarate (DMF) has been applied for decades in the treatment of psoriasis and
now also multiple sclerosis. However, the mechanism of action has remained obscure and
involves high dose over long time of this small, reactive compound implicating many potential
targets. Based on a 1.9 Å resolution crystal structure of the C-terminal kinase domain of the
mouse p90 Ribosomal S6 Kinase 2 (RSK2) inhibited by DMF we describe a central binding
site in RSKs and the closely related Mitogen and Stress-activated Kinases (MSKs). DMF
reacts covalently as a Michael acceptor to a conserved cysteine residue in the αF-helix of
RSK/MSKs. Binding of DMF prevents the activation loop of the kinase from engaging sub-
strate, and stabilizes an auto-inhibitory αL-helix, thus pointing to an effective, allosteric
mechanism of kinase inhibition. The biochemical and cell biological characteristics of DMF
inhibition of RSK/MSKs are consistent with the clinical protocols of DMF treatment.
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Systemic psoriasis treatment with fumaric acid esters hasbeen known for >50 years, and dimethyl fumarate (DMF)is considered the clinically active agent1 (Fig. 1a). Most
recently the European Medicines Agency (EMA) has approved
a new oral formulation of DMF for the treatment of psoriasis
(Procedure No. EMEA/H/C/002157/0000 and see reference2).
DMF has furthermore proven efﬁcacious for the treatment of
relapsing-remitting multiple sclerosis (MS)3. The clinical
response to DMF is slow, with efﬁcacy only appearing after
several weeks to months of high-dose administration1. Several
mechanisms of action (MOA) have been proposed. DMF
reacts, e.g., rapidly with glutathione (GSH)4 and orally admi-
nistered DMF is released into the bloodstream, absorbed by the
cells, and conjugated to GSH5. A proposed MOA for DMF
treatment of MS and psoriasis therefore builds on GSH
depletion increasing hemoxygenase-1 expression, impairing
STAT1 (signal transducer and activator of transcription 1)
phosphorylation, and hereby inhibiting Th1 and Th17 (T
helper cell 1 and 17) differentiation6,7. However, GSH levels
return to normal within 24 h of DMF administration7. DMF
furthermore reduces neutrophil recruitment in inﬂammation8
and reduces microglial and astrocytic inﬂammation9. DMF
inhibition of Th1 and Th17 differentiation has also been
demonstrated through suppression of the NF-κB (nuclear
factor kappa-light-chain-enhancer of activated B cells), p38
MAPK (mitogen-activated protein kinase) and ERK1/2
(extracelluar signal-regulated kinase 1 and 2) signalling
pathways8,10. Along this line, DMF was identiﬁed as a NF-κB
inhibitor11, and more speciﬁcally targeting the C-terminal
kinase domain (CTKD) of the ribosomal S6 kinases (RSKs)12
and mitogen- and stress-activated kinases (MSKs)13.
The closely related RSKs and MSKs belong to the Ras/Raf/
MAPK signalling pathway and encompass four human RSK
isoforms (RSK1–4) and two MSK isoforms (MSK1 and 2)14.
RSK1, 2, and 3 are ubiquitously expressed in human tissues and
RSKs are generally recognized as regulators of proliferative
processes15. MSK1 and 2 are expressed in most cells but at par-
ticularly high levels in cells of the immune system and the central
nervous system. MSK1 and 2 display a key role in the regulation
of IL-10 (interleukin 10) expression by innate immune cells16.
RSKs and MSKs are composed of a N-terminal kinase domain
(NTKD), a linker region and a C-terminal kinase domain
(CTKD), and both kinase domains have adenosine triphosphate
(ATP) binding sites (Fig. 1b). The RSKs are activated by phos-
phorylation of the activation loop in the CTKD by ERK1/217, and
MSKs similarly by ERK1/2 or p38 MAPK. The linker region is
phosphorylated by the activated CTKD, and hereby activates the
NTKD for phosphorylation of downstream targets18.
We ﬁnd that DMF inhibits RSK/MSK kinases primarily by
covalent binding to a conserved cysteine residue placed at an
allosteric site, and that this interaction is likely to represent an
important component of the mechanism of action of DMF as a
clinical drug.
Results
DMF inhibition and modiﬁcation of RSK2CTKD. The efﬁcacy of
DMF and monomethyl fumarate (MMF) as inhibitors against
puriﬁed RSK2CTKD and mutants hereof was evaluated in a well-
established, time-resolved ﬂuorescence resonance energy transfer
(FRET) based kinase activity assay (see Methods). We found that
DMF leads to full inhibition of RSK2 CTKD, but at moderate
efﬁcacy with an IC50, app. of 225 μM, when incubated with
RSK2CTKD prior to ERK2 activation, whereas MMF displayed no
inhibition of RSK2CTKD (Fig. 1c). Considering the high-dose
administration of DMF, the observed effect remains however
relevant. Compared with MMF, the double bond in the α,β-
unsaturated ester of DMF is an excellent (and twofold symmetric)
Michael acceptor (Fig. 1a), which led us to consider if the inhi-
bitory effect on RSK/MSK was due to covalent modiﬁcations of
cysteine residues resulting in a dimethyl 2-S-succinate adduct4.
Indeed, a covalent modiﬁcation was identiﬁed by the reaction of
[2,3-14C]-labelled DMF with the puriﬁed CTKD of RSK2
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Fig. 1 DMF inhibits RSK2. a DMF with Michael acceptor reactive carbons marked with red asterisks. b Schematic representation of RSK2CTKD and position
of cysteine residues. c Inhibition of RSK2CTKD by DMF (squares) and MMF (triangles). Error bars indicate the standard deviation of mean values (n= 3, all
data points included). d Covalent modiﬁcation of RSK2CTKD by DMF. Puriﬁed murine RSK2 (5 nmol) was incubated with 14C-labelled DMF (25 nmol). DMF
binding is reduced by preincubation of RSK2 with 10-fold molar excess of iodoacetamide or GSH, respectively. The + and – signs represent inclusion or
absence of the respective components
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(RSK2CTKD), and the modiﬁcation was diminished when
cysteines were blocked or excess thiol was added (Fig. 1d).
Covalent modiﬁcation of puriﬁed RSK2CTKD by DMF was further
conﬁrmed by mass spectrometry (Table 1). Modiﬁcations of
multiple cysteines (C436, C560, C579, and C599) were observed
by peptide mapping, although complete modiﬁcation was
observed only for C436 and C599.
Crystal structure determination and analysis of RSKCTKD-
DMF. We determined the structure of RSK2CTKD co-crystallized
with excess DMF at 1.9 Å resolution by X-ray crystallography
(Table 2). Overall, the structure resembles that of the inactive
RSK2CTKD (PDB ID 2QR819, RSMD 0.41 Å for all Cα atoms), but
a DMF modiﬁcation of C599 in the α-helix F (αF) was readily
apparent from unbiased electron density maps and further con-
ﬁrmed by the reﬁned structure, as was a less well-deﬁned mod-
iﬁcation site at C436 at the empty ATP binding pocket (Fig. 2a,
b). Focusing on the C599 site, the ester group adjacent to the two-
carbon of the dimethyl 2-S-succinate adduct is stacked to W602,
and a weak hydrogen bond is formed between the linking ester
oxygen and R667 (Fig. 2c). Hydrophobic interactions are fur-
thermore formed with I633 and L710 of αG and αL, respectively.
Thus, the DMF-modiﬁed C599 side chain accommodates a rather
tight binding pocket.
Following a regular activation of the CTKD by phosphoryla-
tion, the phosphorylated threonine in the activation loop forms
an electrostatic interaction with a lysine of the substrate20, hereby
exerting a pull on the activation loop. Structural comparison with
the activated state of related kinases suggests that the activation
loop and αF undergoes large structural rearrangements during
RSK/MSK activation (Supplementary Movie 1 and Fig. 2d). The
C599 site, however, is situated at a central hinge of αF, and
covalent modiﬁcation of C599 by DMF impairs the movement of
the activation loop by steric hindrance (Fig. 2d). Displacement of
the auto-inhibitory αL-helix by disruption of the hydrogen bond
between S603 (αF) and Y707 (αL) are furthermore required for
activation of the RSK2CTKD19,20. A stabilized interaction between
αL and the C-terminal helix bundle via the hydrophobic
interactions between the modiﬁed C599 and L710 of αL
furthermore contribute to the DMF-bound state. However, the
partially occupied DMF modiﬁcation of C436 in the ATP pocket
could also potentially inhibit RSK2 by blocking ATP binding
(Fig. 2a, b). On the other hand, access to C579 in the activation
loop was blocked by a crystal contact and therefore remained
unaccounted for from the crystal structure analysis.
In vitro studies of cysteine mutants. To further clarify the
mechanism and which cysteine residues that are sufﬁcient and
responsible for the inhibitory effect of DMF, we turned to further
activity assays combined with cysteine mutant forms. Cysteine
mutants were designed on the basis of sequence alignments and
activity assays (Supplementary Fig. 1), generally favouring
cysteine-to-valine mutations over, e.g., serine and alanine sub-
stitutions. DMF displayed no efﬁcacy against the activated form
of RSK2 as to be expected from a mutual antagonism of C599
modiﬁcation and activation loop docking (see above, Fig. 3).
Similarly, no effect of DMF, even at 10 mM DMF saturating
conditions, was observed when screened against a panel of
kinases, including full-length activated RSK1, RSK2, and MSK1
(Supplementary Fig. 2). Combined mutations of all cysteines
except C599 (RSK2CTKD C436V, C439V, C560V, and C579V,
denoted tetra-cysteine mutant) showed DMF efﬁcacy comparable
to WT over time, conﬁrming that the allosteric site at C599 is
slowly modiﬁed and resulting in a stable inhibition (Fig. 3).
Mutation of C599 only (C599V) displayed the same degree of
inhibition as WT following 1 h of incubation suggesting that
modiﬁcation of other cysteines also can cause inhibition. How-
ever, unlike for WT and the tetra-cysteine mutant this inhibition
was gradually diminished over time (Fig. 3).
Cellular studies of cysteine mutants. We furthermore evaluated
selected mutations of full-length RSK2 and MSK1 in HEK293
cells (Fig. 4). The activity of the C-terminal kinase domains was
evaluated by linker region serine phosphorylation (S386 and S376
for RSK2 and MSK1, respectively) following stimulation by epi-
dermal growth factor (EGF). DMF inhibition of RSK2 remained
when C436 in the ATP binding pocket was mutated (C436V) and
the same effect was observed for the C579V mutation in the
Table 1 Degree of in vitro modiﬁcation of cysteines in RSK2CTKD by DMF on puriﬁed RSK2CTKD (DMF1 mM) and in HEK293 cells
(DMF 140 µM) estimated by mass spectrometry (n= 1)
Residue Site In vitro modiﬁcation (%) Cellular modiﬁcation (%)
C436 and C439 ATP pocket 95.4 n.d.
C560 ATP pocket 88.3 0.7
C579 Activation loop 78.8 23.9
C599 Allosteric site 99.8 48.4
Table 2 Crystallographic data collection and reﬁnement
statistics
Murine RSK2:DMF
Data collectiona
Space group P41212
Cell dimensions
a, b, c (Å) 47.0, 47.0, 291.9
α, β, γ (°) 90, 90, 90
Resolution (Å) 40–1.9 (2.0–1.9)b
Rsym (%) 4.5 (54.9)
Rp.i.m. (%) 1.3 (32.1)
I/σI 23.3 (2.3)
Completeness (%) 99.4 (96.5)
Redundancy 8.6 (8.5)
Reﬁnement
Resolution (Å) 40–1.9
No. reﬂections 27,094
Rwork/Rfree (%) 20.5/25.0
No. atoms
Protein 2428
Ligand/ion 21
Water 121
B-factors (Å–2)
Protein 64.5
Ligand/ion 80.7
Water 62.6
R.m.s. deviations
Bond lengths (Å) 0.009
Bond angles (°) 1.44
aData were collected from a single crystal
bValues in parentheses indicate the outer resolution bin
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activation loop although yielding lower EGF-stimulated activity.
However, mutation of C599 abolished the inhibitory effect of
DMF (Fig. 4a, c). Similarly, mutation of the corresponding
cysteine in MSK1 (C603V) abolished the effect of DMF (Fig. 4b,
d), suggesting this allosteric site is the key target for DMF in the
RSKs and MSKs. Mutation of C583 in the activation loop of
MSK1 also diminished the effect of DMF, which may indicate
that p38 MAPK or ERK1/2 phosphorylation of the activation
loop additionally is sensitive to DMF modiﬁcation. Modiﬁcation
of this cysteine could also explain the initial DMF inhibition
observed for the puriﬁed C599V mutant of RSK2CTKD (Fig. 3).
The cysteine in the activation loop is positioned penultimate to
the threonine that is phosphorylated by upstream activating
kinases, and it is solvent exposed as observed in the structure of
the complex between RSK1 and ERK221. The covalent
modiﬁcation of RSK2 at the major, allosteric site at C599 was
furthermore conﬁrmed by MS analysis and peptide mapping of
HEK293 cells treated with DMF (Table 1). In cells treated with
DMF, no modiﬁcation is, however, observed for the C436, C439,
and C560 sites, which is likely due to bound ATP present at
millimolar concentration in the cell thus blocking DMF from
accessing these cysteines.
Discussion
The characteristics of DMF inhibition that we describe here are in
good agreement with the slow response to DMF in clinical
treatment1. We propose that the tightly packed environment of
the DMF-modiﬁed C599 site (RSK2) provides a robust inhibition
of RSK/MSK kinases (Fig. 5). The late onset of DMF efﬁcacy in
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patients could originate from GSH competition and many other
off-target reactions leading to only a slow saturation of the C599
target site. Although we have established a consistent model for
DMF inhibition of RSK/MSK kinases, we also acknowledge that
DMF may target additional pathways and functionalities in the
cell. We note, however, that for a Michael addition to proceed, it
requires a stable positioning of DMF to the target cysteine resi-
due. Only a few kinases containing a cysteine corresponding to
C599 and bearing structural resemblance to the RSK/MSK family
were identiﬁed in a multiple sequence alignment of the human
kinome. A closer comparison of the equivalent cysteine site in the
structures or homology models of these kinases revealed that the
putative DMF binding pocket diverge from that of the RSKs and
MSKs and likely do provide favourable interaction sites (Sup-
plementary Fig. 3). We therefore predict that only few speciﬁc
sites entail the important, physiological effects of DMF, and that
the allosteric C599 site of the RSK and MSK families is one such
site. This is further augmented by the lack of inhibition observed
in the broad kinase panel screen, even at 10 mM DMF (Supple-
mentary Fig. 2).
The structural identiﬁcation and characterization of the allos-
teric binding site at C599 invites a rational development of novel
and more speciﬁc compounds based on the DMF mechanism and
the efﬁcacy of a slow off-rate due to a covalent mode of action,
which from clinical applications is known to be tolerated. The
reactive and sensitive nature of the allosteric site described
here may also hint at a role in endogenous mechanisms of reg-
ulation of the MAPK pathway.
Methods
RSK2 puriﬁcation. The C-terminal kinase domain of murine RSK2 (residues
400–740) including a N-terminal polyhistidine tag (His8), a linker (DYDIPTT) and
a Tobacco Etch Virus (TEV) protease site (Glu-Asn-Leu-Tyr-Phe-Gln-Gly) in
PET-22b was purchased from Genscript (RSK2-pET-22b). Val and Ser were gen-
erally the most frequent substitutions of C436, C439, C560, C579, and C599 in a
multiple sequence alignment of the CamKII kinase family (Supplementary Fig. 1)
and mutants were generated with the QuikChange Lightning Kit (Agilent Tech-
nologies). The Val mutants generally displayed the best ERK2 activation and were
therefore used as indicated.
IC
50
 (
μM
) 
0
100
200
300
400
500
600
700
800
900
RSK2CTKD
WT
RSK2CTKD
C599V
RSK2CTKD
C436V, C439V,
C560V, C579V 
p < 0.05
p < 0.05 p < 0.05
Fig. 3 Time course of DMF inhibition. In vitro determination of apparent
IC50 values of DMF on RSK2CTKD activity following incubation with DMF at
different time points (1 h: black, 24 h: dark grey, and 48 h light grey) prior to
ERK2 activation (n= 3, all data points indicated by circles)
EGF (30 min)
DMF
–
–
–
+
+
–
+
+
+
–
+
+
+
–
+
+
+
–
+
+
P-MSK1 (S376)
GST-MSK1
M
SK1
W
T
M
SK1
C440T
M
SK1
C583V
M
SK1
C603V
b
d
Endogenous MSK1
a
c
EGF (15 min)–
–
–
+
+
–
+
+
+
–
+
+
+
–
+
+
+
–
+
+
P-RSK2 (S386)110
kDa kDa
80
110
110
80
110GST-RSK2
RSK2
W
T
RSK2
C436V
RSK2
C579V
RSK2
C599V
DMF (1 h)
Plasmid
Endogenous RSK2
Ac
tiv
ity
 re
la
tiv
e 
to
 W
T 
(%
)
0
20
40
60
80
100
120
140
Ac
tiv
ity
 re
la
tiv
e 
to
 W
T 
(%
)
40
20
60
80
100
120
140
160
180
p < 0.01
p < 0.01
p < 0.01
p < 0.01
p < 0.01 p < 0.01 p < 0.01 p < 0.01 p = 0.02 p < 0.01 p = 0.14p = 0.09n.a. p = 0.38
EGF
DMF
Plasmid
EGF
DMF
Plasmid
–
–
+
–
+
+
+
–
+
+
+
–
+
+
+
–
+
+
–
+
RSK2 WT RSK2
C436V
RSK2
C579V
RSK2
C599V
0
MSK1WT MSK1
C440T
MSK1
C583V
MSK1
C630V
–
–
+
–
+
+
+
–
+
+
+
–
+
+
+
–
+
+
–
+
Fig. 4Mutational studies of DMF inhibition in cells. Mutational analysis of HEK293 cells transfected with RSK2, MSK1, or cysteine mutants hereof. HEK293
cells were supplemented with DMF (140 μM) and stimulated with epidermal growth factor (EGF, 1 ng ml–1). a, b Representative western blots from RSK2
and MSK1 mutational analysis respectively. c, d RSK2CTKD and MSK1CTKD activity determined as the autophosphorylation of S386 and S376, respectively,
relative to WT. The activity of EGF-induced wild-type was set to 100% (n= 5 and n= 4, respectively; all data points indicated by black, ﬁlled circles)
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06787-w ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:4344 | DOI: 10.1038/s41467-018-06787-w |www.nature.com/naturecommunications 5
BL21 (DE3) Rosetta was transformed with RSK2-pET-22b and plated on
lysogeny broth (LB) agar plates supplemented with 50 μg ml–1 ampicillin (Amp)
and 35 μg ml–1 Chloramphenicol (Cam). Five colonies were used for inoculation
of a 20 ml LB medium overnight culture supplemented with 100 μg ml–1 Amp
and 35 μg ml–1 Cam. Two litres of LB, supplemented with 100 μg ml–1 Amp and
35 μg m–1l Cam, was inoculated with the overnight culture and grown at 37 °C.
Expression was induced with 0.1 mM isopropyl β-D-1-thiogalactopyranoside at
an optical density of A600 nm= 0.8 and the temperature was lowered to 20 °C for
3 h and further lowered to 12 °C for 20 h. In all, 8 g cells were harvested from 2 l
of culture and resuspended in 100 ml of lysis buffer (50 mM Tris-HCl, 100 mM
NaCl and 5 mM β-mercaptoethanol, pH 7.5). Cells were lysed by high-pressure
homogenization (three times at 15,000 psi) in lysis buffer supplemented with 1
mM phenylmethanesulfonyl ﬂuoride (PMSF) and 5 μg ml–1 DNase I. The lysate
was cleared of cell debris and aggregates by centrifugation at 25,000 g for 45 min.
In total, 5 ml of Ni2+-beads slurry (Ni-sepharose 6 Fast Flow, GE Healthcare)
were washed in equilibration buffer (20 mM Tris-HCl, 100 mM NaCl, 5 mM β-
mercaptoethanol, pH 7.5) and incubated with supernatant for 1 h at room
temperature. The supernatant and Ni2+-beads were poured into a Poly-Prep
column (Bio-Rad) and washed with 100 ml equilibration buffer. RSK2 was eluted
in two times 5 ml elution buffer (20 mM Tris-HCl, 100 mM NaCl, 5 mM β-
mercaptoethanol, 500 mM imidazole, pH 7.5). The eluate was supplemented
with 1 mg of recombinant TEV and immediately dialysed against 1 litre of
equilibration buffer overnight at room temperature. Digested and dialysed RSK2
was loaded on the Ni-beads in the Poly-Prep column and RSK2 was collected in
the ﬂow through. RSK2 was concentrated by ultraﬁltration (Vivaspin 6, 30 kDa
cutoff). Protein concentration was evaluated by spectrophotometry (Nanodrop,
Thermo Fisher Scientiﬁc) assuming εRSK2= 44,350 cm−1 M−1 and MRSK2= 38.4
kDa. Size exclusion chromatography (SEC) was performed on a Superdex 200
10/300 GL (GE Healtcare) column in SEC buffer (10 mM Tris-HCl, 50 mM
NaCl, 5 mM β-mercaptoethanol, pH 8.0) at room temperature. Fractions
containing RSK2 were concentrated by ultraﬁltration to 10 mg ml−1 (Vivaspin 6,
30 kDa cutoff) and during concentration the buffer was exchanged to 10 mM
Tris-HCl, 10 mM β-mercaptoethanol, pH 8.0. RSK2 was aliqouted, ﬂash frozen
in liquid N2 and stored at −80 °C. RSK2 purity was evaluated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using a 15% separation
gel. RSK2 was dialysed into reaction buffer (10 mM Tris-HCl pH 8.0 and 5 mM
Tris(2-carboxyethyl)phosphine (TCEP)) in a slide-A-lyzer (Thermo Fisher
Scientiﬁc) prior to reaction with DMF for ligand assays and crystallization. The
puriﬁcation procedure resulted > 95% pure and stable RSK2 evaluated by PAGE
in SDS buffer and mass spectrometry.
14C-labelled DMF synthesis. In a ﬂame-dried ﬂask under argon atmosphere, 1 mg
(8.5 µmol) of [2,3-14C]-labelled fumaric acid (55 mCi mmol–1, Moravek Bio-
chemicals), and 4 mg (34 µmol) non-labelled fumaric acid were dissolved in
MeOH. Subsequently, BF3·OEt2 (21 µl, 172 µmol, 4 eq.) was added and the mixture
was reﬂuxed. After 16 h, the reaction was quenched and adjusted to pH 8 via a 5%
aq. NaHCO3 solution. The resulting mixture was extracted with dichloromethane
(6 × 3 ml) and evaporated to dryness in vacuo affording DMF in 80% yield. [2,3-
14C]-labelled DMF was dissolved in dimethylsulfoxide (DMSO) resulting in a ﬁnal
concentration of 100 mM. The procedure was repeated in parallel utilizing non-
labelled fumaric acid. Characterization of the non-labelled DMF was performed.
The obtained NMR data were in accordance with known literature values for DMF.
1H NMR (400 MHz, CDCl3) δ 6.85 (s, 2H), 3.80 (s, 6H); 13C NMR (100MHz,
CDCl3) δ 165.5, 133.5, 52.4.
Radiolabelled ligand assays. Reactions were performed in reaction buffer in a
total volume of 25 μl. In all, 5 nmol of RSK2 dialysed into reaction buffer was
mixed with 25 nmol [2,3-14C]-labelled DMF and incubated for 30 min. Control
experiments were performed by preincubation of 5 nmol RSK2 with 50 nmol
iodoacetamide (Sigma-Aldrich) and 25 nmol [2,3-14C]-labelled DMF with 50 nmol
reduced GSH pH 8.0 (Sigma-Aldrich) for 30 min prior to reaction with [2,3-14C]-
labelled DMF and RSK2 respectively. Covalent modiﬁcation of RSK2 by [2,3-14C]-
labelled DMF was evaluated by PAGE-SDS using a 15% separation gel. A storage
phosphor screen (Molecular Dynamics) was exposed to the gel for 48 h and
scanned in a Typhoon Trio (GE Healthcare). The experiment was repeated three
times (n= 3) and a representative blot is depicted.
Crystallization. The RSK2–DMF complex was formed by incubating RSK2 (8 mg
ml–1) dialysed into reaction buffer with 5 mM DMF for 30 min at room tem-
perature. Aggregates were removed by centrifugation at 15,000 g for 5 min. Initial
screening was performed using Index screen (Hampton Research) where 1 μl RSK2
was mixed with 1 μl reservoir solution and equilibrated against 500 μl reservoir
using the sitting-drop vapour-diffusion method at 19 °C. An initial crystal hit was
obtained in condition #43 (0.1 M Bis-Tris pH 6.5 and 25% (w/v) polyethylene
glycol (PEG) 3350). The size and diffraction properties of the crystals were opti-
mized with Additive Screen HT (Hampton Research) with condition #19 (0.05 M
NaF). Crystals were reproducibly obtained in the described condition at a size
suitable for data collection.
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Data collection, processing, and reﬁnement. Crystals were mounted in nylon
loops from mother liquor supplemented with 20% (v/v) ethylene glycol and ﬂash
cooled in liquid N2. A complete data set was collected at 100 K on the X06SA
beamline at the Swiss Light Source (Paul Scherrer Institute). The diffraction images
were indexed using XDS22 and the reﬂections were scaled in SCALA23. Molecular
replacement was performed with the program PHASER24 and a search model derived
from PDB ID 2QR819. Rigid body reﬁnement, full model reﬁnement, and calculation
of omit maps were performed in the PHENIX suite25. Model building and analysis
was performed with Coot26. Root mean square deviations were calculated, super-
positions were performed, and structural ﬁgures were prepared using PyMOL
(Schrödinger; http://www.pymol.org). The ﬁnal structure had 97% of amino-acid
residues in favourable region of the Ramachandran plot, and remaining 3% in the
additionally allowed region as indicated by Molprobity27.
Bioinformatics. A multiple sequence alignment of kinases with at least 25%
sequence identity to RSK2 was prepared with PSI-BLAST with the CTKDRSK2 as
query against the human kinome and searched for kinases with a cysteine corre-
sponding to C599 (Supplementary Fig. 1). A homology models of the activated
state of RSK2 was prepared in Modeller28 based on PDB ID 3A62. The morph
between the inactive state of RSK2 (PDB ID 2QR8) and the homology model of the
activated state was prepared in morphinator (http://morphinator.au.dk)29.
In vitro assay. In vitro activity of murine RSK2CTKD was evaluated in the HTRF-
KinEASETM assay (Cisbio Bioassays). Evaluation of the effect of DMF and MMF
on activated RSK2CTKD was performed by activation of RSK2CTKD (2 μM) in
reaction buffer with ERK2 (0.1 μM) (Signalchem) with 200 μM ATP and 10mM
MgCl2 in kinase buffer (50 mM HEPES pH 7.0, 2 mM TCEP, 3 mM NaN3, 0.01%
BSA, and 0.1 mM Na3VO4) for 1 h at 37 °C. In all, 50 ng activated RSK2CTKD was
mixed with DMSO or a concentration series of DMF in kinase buffer for 1 h at
room temperature in 384-well plates for ﬂuorescence (Greiner). The reactions were
started by addition of ATP (100 μM), STK1 substrate (0.1 μM) resulting in 10 μl
reactions. The reactions were stopped after 20 min at room temperature with
Streptavidin-XL665 in EDTA (5 μl) and STK antibody cryptate (5 μl). Evaluation of
the effect of DMF on the inactive state of RSK2CTKD was evaluated by incubation
of RSK2CTKD in reaction buffer with DMSO or a concentration series of DMF in
kinase buffer followed by ERK2 activation and kinase reaction as described above.
IC50 values were calculated by non-linear regression using sigmoid concentration
response in Graph pad Prism 7. All experiments were repeated at least three times
(n= 3) and variance and two-tailed Student's t-test were applied in the statistical
analysis.
Kinase panel screening. Kinase selectivity proﬁling for DMF was carried out as
adviced (http://www.kinase-screen.mrc.ac.uk/). Brieﬂy, protein kinase assays were
carried out at room temperature (21 °C) and were linear with respect to time and
enzyme concentrations under the conditions used. Assays were performed for 40
min using a Biomek 2000 Laboratory Automation Workstation in a 96-well format
(Beckman Instruments, Palo Alto, CA, U.S.A.). The concentration of magnesium
acetate in the assays was 10 mM, while the concentration of [γ-33P]-ATP (800 cpm
pmol–1) used was selected to be close to the kinase’s Km for ATP. Assays were
initiated with Mg2+-ATP and stopped by the addition of 5 µl of 0.5 M ortho-
phosphoric acid. Aliquots were then spotted on to P30 ﬁltermats, washed four
times in 75 mM phosphoric acid to remove ATP, once in methanol, then dried and
counted for radioactivity30.
Analysis of mutants. Mutational analysis of MSK1 and RSK2 was performed in a
mammalian expression vector (pEBG2T) in which a glutathione S-transferase (GST)
domain and FLAG-tag (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys) was fused to the N-
terminus of human MSK1 (GST-FLAG-MSK1). The positions corresponding to
C436, C579, and C599 in human RSK2 of human MSK1 (C440, C583, and C603)
were mutated to Val, Ser, and Thr using the QuikChange Lightning Kit (Agilent
Technologies). The Val mutants generally displayed the best ERK2 activation.
Human embryonic kidney cells (HEK293) were cultured in tissue culture ﬂasks
(150 cm2) to 60% conﬂuence in Dulbecco's modiﬁed Eagle's medium (DMEM,
Gibco) supplemented with 50 units ml–1 penicilin G (Gibco), 50 μg ml–1
streptomycin (Invitrogen), 5 μg ml–1 gentamycin (Gibco), 10% (v/v) foetal bovine
serum (FBS, Gibco), and 2.5% HEPES (Gibco). Cells were trypsinated and seeded
in 10 cm Petri dishes at a density of 6.5 × 106 cells per dish in 10 ml DMEM
supplemented with 50 μg ml–1 bovine pituitary growth hormone (BGH, Gibco),
antibiotics (penicilin G, streptomycin, gentamycin), 2% FBS, and 2.5% HEPES and
were incubated for 2 days. The culture medium was changed to DMEM
supplemented with 2.5% HEPES for 16 h. Transfection with plasmids was
performed as previously described31 with modiﬁcations. HEK293 cells were
transfected using 3.5 μg plasmid DNA/dish dissolved in 250 μl Optimem
(Invitrogen) and 30 μl Lipofectamine 2000 (Invitrogen) dissolved in 250 μl
Optimem added together for 20 min before transferring to cells. The Lipofectamine
and DNA complexes were incubated with cells for 6 h at 37 °C and 5% CO2. Cell
culture medium was then changed back to DMEM special growth medium with
BGH, antibiotics, 2% foetal calf serum, and 2.5% HEPES for 48 h.
DMF (Sigma-Aldrich) was dissolved in 40% (v/v) DMSO (Merck) resulting in a
70 mM stock solution and diluted 10-fold in culture medium. All stock solutions
were freshly made 10 min before use. HEK293 cells (ATCC® CRL-1573) were either
left untreated or were pre-incubated with 140 μM of DMF for 1 h and stimulated12
for either 15 min (RSK2) or 30 min (MSK1) with 1 ng ml–1 of human recombinant
EGF (Pepro Tech, UK). Cells were stopped after one wash with ice-cold phosphate-
buffered saline and ﬂash frozen in liquid nitrogen. Whole-cell extracts were
prepared by adding 400 μl of 1 × cell lysis buffer (Cell Signaling Technology) to
each 10 cm dish. The 1 × lysis buffer was supplemented with 22 μl protease
inhibitor cocktail (EDTA-free complete, Roche Diagnostics), and 10 µl PMSF per
ml buffer. The collected samples were added 1 µl Benzonase per 400 µl buffer
(MERCK, Denmark), sonicated and centrifuged for 10 min at 4 °C at 10,000 g and
the supernatants were saved for protein determination. Equal loads of protein (50
µg) were separated on pre-cast gels, SDS-Page 8–16% (Invitrogen). Proteins were
blotted onto Hybond nitrocellulose membrane (Amersham). Antibodies for
western blotting were all from Cell Signaling, Beverly, MA, USA: anti-phospho-
MSK1 (Ser376, #9591, 1:750), anti-phospho-RSK2 (Ser386, #9341, 1:750), and
mouse anti-GST (26H1, #2624, 1:2000); HRP anti-rabbit (#7074, 1:2000), anti-
mouse (#7076, 1:2000). GST-RSK2 and GST-MSK1 full-length protein of about
116 kDa were identiﬁed. Antibody binding was visualized13 by horseradish
peroxidase-conjugated second antibody in a standard ECL™ (RPN 2106) reagent on
Hyperﬁlm™ enhanced chemoluminescence (RPN 3103K, Amersham Bioscience),
and densitometric analysis of the band intensity was carried out using Kodak one-
dimensional imaging analysis software. Graphs were made with Sigma Plot v.11.
STATA v.14 was used to test for normal distribution and for performing Student’s
t-tests. A probability of P < 0.05 was regarded as statistically signiﬁcant. Uncropped
western blots are shown in Supplementary Fig. 4.
Mass spectrometry. Puriﬁed murine RSK2 was treated with 1 mM DMF or
DMSO (vehicle) and left for 2 weeks. Samples were digested with chymotrypsin.
From a single peptide mapping experiment (Alphalyse A/S, Odense, Denmark) it
was possible to identify C436, C560, C579, and C599 with DMF modiﬁcations,
whereas no peptides containing C439 were detected.
GST-RSK2 was expressed in HEK293 cells as for the mutational analyses (see
below) with the difference that HEK293 cells were transfected with 6 µg of human
GST-RSK2 plasmid DNA per dish. For afﬁnity puriﬁcation, an amount of 5.6 mg
total protein from not stimulated (empty vehicle) or from DMF-stimulated cells
was suspended in 8 ml of 1 × Lysis buffer and was added 1 ml of glutathione-
sepharose 4B beads (GE 17-0756-05, GE Healthcare Life Science) each and rotated
for 30 min on ice. Glutathione-sepharose 4B beads were previously equilibrated in
wash and binding buffer (100 mM Tris-Base pH 7.4, 0.15 M NaCl, 1 mM EDTA).
Unbound sample was removed by centrifugation 500 g for 2 min. Sepharose 4B
beads were washed with 10 ml of wash buffer two times and centrifuged at 500 g for
2 min. Proteins were eluted in two steps, step one: elution buffer of 50 mM Tris-
HCl and 20 mM reduced GSH (Sigma-Aldrich), pH 8.0, and step two: elution
buffer with 50 mM reduced GSH, 6 ml of each. The eluted protein samples were
immediately dialysed for wash buffer and overnight in Slide-A-Lyzer 10 K Dialysis
Casettes (No.66810 Thermo Fisher Scientiﬁc). The next day, proteins were freeze
dried in portions of 1 ml and re-dissolved in 40 µl of 50 mM TCEP in SDS loading
buffer+ 60 µl of native buffer (Bio-Rad #161-0738) and analysed on PAGE-SDS
8–16% Tris-glycin gels. The proteins were stained by Page Blue Protein Staining
Solution (Thermo Fisher Scientiﬁc Inc). Purity was controlled by western blotting.
Proteins run on the same gel, treated by vehicle or DMF, were blotted to a
nitrocellulose membrane and tested with monoclonal antibody for RSK2 (Santa
Cruz Biotechnology sc-9986, 1:1000) and antibody for GST (Cell Signaling #2624S,
1:2000) to identify the full-length protein of about 116 kDa. Step two elution
contained a bulk amount of GST-RSK2 and gel pieces were cut out. After in-gel
digestion by trypsin or chymotrypsin and by nano-HPLC-ESI-MS/MS (Proteome
Factory, Berlin), DMF modiﬁcations of the ﬁve cysteine peptides were identiﬁed by
the chymotrypsin digests and comparing signals from the unmodiﬁed peptides in
the vehicle with DMF-treated samples in a single comparison experiment (n= 1).
The degree of modiﬁcation of the peptide containing C436 and C439 could not be
determined due to the hydrophilic nature of this peptide.
Data availability
The data that support the ﬁndings of this study are available from the corresponding
author upon request. The reﬁned coordinates and crystallographic data are available in
the Protein Data Bank (PDB) with access code 5O1S.
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